Affinia Therapeutics Secures Health Canada Clearance to Launch UPBEAT© Phase 1/2 Trial Evaluating AFTX-201 for BAG3-Related Dilated Cardiomyopathy
Affinia Therapeutics, a clinical-stage biotechnology company focused on advancing next-generation gene therapies for serious cardiovascular diseases, has announced a key regulatory milestone with the approval of its clinical trial application (CTA) by Health Canada. The authorization enables the company to initiate clinical evaluation of AFTX-201, an investigational gene therapy designed to treat patients with BAG3-associated dilated cardiomyopathy (DCM), a rare and life-threatening inherited heart condition.
This development marks a significant step forward in Affinia’s mission to deliver innovative genetic medicines that address the root causes of disease. AFTX-201 is being developed as a potential best-in-class therapy aimed at restoring normal cardiac function in patients whose condition is driven by mutations in the BAG3 gene. BAG3-associated DCM is characterized by progressive weakening of the heart muscle, often leading to early-onset heart failure and a heightened risk of premature death. Despite its severity, current treatment options remain limited and largely focus on managing symptoms rather than correcting the underlying genetic defect.
At the core of AFTX-201 is a sophisticated gene delivery platform utilizing adeno-associated virus (AAV) technology. The therapy is engineered to deliver a fully human, full-length BAG3 transgene directly to cardiac tissue. What distinguishes this approach is Affinia’s proprietary capsid design, which has been optimized for efficient cardiac transduction at significantly lower doses compared to traditional AAV-based systems such as AAV9 or AAVrh74. By achieving effective gene delivery at doses estimated to be five- to ten-fold lower than conventional vectors, AFTX-201 aims to improve both safety and therapeutic impact, potentially reducing the risk of immune responses and other dose-related complications.
The clinical evaluation of AFTX-201 will take place within the UPBEAT© clinical trial, a study designed to assess both the safety and efficacy of the therapy in patients living with BAG3-associated DCM. The treatment is administered as a one-time intravenous infusion, reflecting a growing trend in gene therapy toward durable, potentially curative interventions that minimize the need for repeated dosing. If successful, this approach could represent a paradigm shift in the management of inherited cardiomyopathies, offering patients a long-term solution rather than chronic disease management.
Preclinical data supporting AFTX-201 have been highly encouraging. In animal models of BAG3-associated disease, the therapy demonstrated the ability to significantly increase BAG3 protein expression in cardiac tissue. More importantly, these studies showed a complete restoration of cardiac function, highlighting the potential of AFTX-201 to reverse the pathological effects of the disease at a fundamental level. While clinical outcomes in humans remain to be determined, these findings provide a strong scientific rationale for advancing the therapy into human trials.
The importance of developing targeted therapies for BAG3-associated DCM has been emphasized by leading experts in the field. Rafik Tadros, a prominent figure in cardiovascular genetics and Director of the Cardiovascular Genetics Centre at the Montréal Heart Institute, highlighted the urgent unmet need faced by patients with this condition. He noted that BAG3 DCM is a serious inherited disorder with high mortality, often progressing rapidly to heart failure. Crucially, there are currently no approved treatments that directly address the genetic basis of the disease, underscoring the potential significance of therapies like AFTX-201.
The CTA approval in Canada builds upon a series of recent regulatory advancements for AFTX-201 across major global markets. In the United States, the therapy has already received clearance from the U.S. Food and Drug Administration, which accepted Affinia’s Investigational New Drug (IND) application. In addition, the FDA granted Fast Track designation to AFTX-201, a status intended to expedite the development and review of therapies that address serious conditions and fulfill unmet medical needs. This designation may facilitate more frequent interactions with regulators and potentially accelerate the path to approval if clinical data prove favorable.
Further reinforcing its global development strategy, Affinia has also secured Orphan Drug designation from the European Medicines Agency. This designation is granted to therapies targeting rare diseases and provides a range of incentives, including regulatory support, market exclusivity, and potential financial benefits. Together, these regulatory milestones reflect growing recognition of both the severity of BAG3-associated DCM and the promise of AFTX-201 as a novel therapeutic approach.
According to Hideo Makimura, Chief Medical Officer of Affinia Therapeutics, the CTA approval represents a critical step in the company’s clinical development journey. He emphasized that the organization is actively collaborating with clinical investigators and trial sites across both the United States and Canada to initiate patient enrollment in the UPBEAT trial. The goal is to begin dosing patients in the near term, advancing the therapy from preclinical success to real-world clinical evaluation.
Makimura also highlighted the broader vision behind AFTX-201, describing it as a potentially transformative treatment that could meaningfully improve the lives of patients with BAG3-associated DCM. By targeting the genetic root cause of the disease, the therapy has the potential not only to halt disease progression but also to restore cardiac function, offering hope for outcomes that go beyond what is achievable with existing standard-of-care therapies.
The advancement of AFTX-201 reflects a broader evolution in the field of cardiovascular medicine, where genetic insights are increasingly informing the development of precision therapies. As gene therapy technologies continue to mature, they are opening new possibilities for treating conditions that were previously considered intractable. Affinia’s work in this area positions the company at the forefront of a new wave of innovation aimed at addressing the underlying drivers of disease rather than merely managing symptoms.
With regulatory approvals now in place across multiple regions, the focus shifts to the successful execution of the UPBEAT clinical trial and the generation of robust clinical data. The outcomes of this study will be closely watched by clinicians, researchers, and patients alike, as they will help determine whether AFTX-201 can fulfill its promise as a first- or best-in-class therapy for BAG3-associated dilated cardiomyopathy.
In summary, the CTA approval by Health Canada represents a pivotal milestone for Affinia Therapeutics and its AFTX-201 program. It not only enables the initiation of clinical trials in Canada but also reinforces the global momentum behind the therapy’s development. As the company moves forward with patient enrollment and dosing, AFTX-201 stands as a compelling example of how advances in gene therapy could redefine the treatment landscape for rare and devastating cardiovascular diseases.
About the UPBEAT© clinical trial
The UPBEAT© clinical trial is a multicenter, single-arm open-label Phase 1/2 clinical trial designed to evaluate the safety, tolerability, pharmacodynamics, and preliminary efficacy of AFTX-201 in adults with genetically confirmed BAG3-associated dilated cardiomyopathy. The trial includes a dose-exploration phase followed by a dose-expansion phase. All participants will receive a single intravenous infusion of AFTX-201 at a dose that has been deemed safe and efficacious based on preclinical studies. The primary objective of the trial is to evaluate safety and tolerability through 52 weeks following administration.
Secondary and exploratory objectives include pharmacodynamic and preliminary efficacy assessments, which will be evaluated as changes from baseline. Study design, dose selection, and monitoring plans are informed by input from patients, clinicians, and regulators and by completed nonclinical proof-of-concept, biodistribution, and safety studies, which demonstrated complete correction of heart ejection fraction to normal (wild type) level and adequate safety margin for the doses being explored in the clinical trial.
Protocol-defined stopping rules, centralized safety data review, and oversight by an independent Data Safety Monitoring Board are implemented to ensure the safety of participants. Multiple trial sites across the U.S. and Canada are planned to be available. Travel arrangements can be made for interested participants not living near a trial site. Interested participants who have a BAG3 mutation, are 18 – 55 years old, and not able to perform normal activities are encouraged to reach out via clinicaltrials@affiniatx.com.
About BAG3 DCM
BAG3 dilated cardiomyopathy (DCM) is a serious, inherited heart condition with a high mortality rate and a significant unmet medical need. The disease affects more than 70,000 patients in the Canada, E.U., U.S., and U.K. regions. The BAG3, or Bcl2-associated athanogene 3, gene encodes for a protein that is critical to the normal structure and function of heart cells. Patients with BAG3 DCM have a mutation in the BAG3 gene and a deficiency in functional BAG3 protein, resulting in early onset heart failure that progresses rapidly. Despite current standard of care, almost 25% of patients require a heart transplant.
About Affinia Therapeutics
Affinia Therapeutics is a clinical-stage biotech company pioneering a shift to a new class of rationally designed gene therapies that treat rare and prevalent diseases. Affinia Therapeutics’ pipeline of first-in-class or best-in-class product candidates, initially in cardiovascular diseases, leverages its proprietary next-generation capsids, payloads, or manufacturing approaches and have shown efficacy, safety, and differentiation in relevant animal models.
Source Link:https://www.businesswire.com/
